A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease - Trial NCT05595642
Access comprehensive clinical trial information for NCT05595642 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Hoffmann-La Roche and is currently Recruiting. The study focuses on Chronic Obstructive Pulmonary Disease (COPD). Target enrollment is 1290 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hoffmann-La Roche
Timeline & Enrollment
Phase 2/3
Dec 29, 2022
Jun 01, 2025
Primary Outcome
Annualized rate of moderate and severe COPD exacerbations over the 52-week treatment period
Summary
This study will evaluate the efficacy and safety of astegolimab compared with placebo in
 participants with chronic obstructive pulmonary disease (COPD) who are former or current
 smokers and have a history of frequent exacerbations.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05595642
Non-Device Trial